Apixaban - Pfizer

Drug Profile

Apixaban - Pfizer

Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes

Most Recent Events

  • 20 Jun 2017 Bristol-Myers Squibb initiates enrolment in the phase III AXADIA trial in Stroke and Thromboembolism (in patients with Atrial fibrillation and End-Stage Kidney Disease) in Germany (PO) (NCT02933697)
  • 13 Apr 2017 Pfizer and Bristol-Myers Squibb completes the phase III AVERROES trial in Stroke (Prevention) in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, South Korea, Malaysia, Mexico, Norway, Philippines, Poland, Russia, Singapore, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine and United Kingdom (PO) (NCT00496769) (EudraCT2007-001557-26)
  • 23 Feb 2017 Bristol-Myers Squibb has patent protection for apixaban in Japan (Pfizer Form 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top